Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKibo Energy Regulatory News (KIBO)

Share Price Information for Kibo Energy (KIBO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.0175
Bid: 0.015
Ask: 0.02
Change: -0.0025 (-12.50%)
Spread: 0.005 (33.333%)
Open: 0.02
High: 0.02
Low: 0.0165
Prev. Close: 0.02
KIBO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Kibo Subsidiary Announces Business Update

21 May 2024 07:00

RNS Number : 1780P
Kibo Energy PLC
21 May 2024
 

Kibo Energy PLC (Incorporated in Ireland)

(Registration Number: 451931)

(External registration number: 2011/007371/10)

LEI Code: 635400WTCRIZB6TVGZ23

Share code on the JSE Limited: KBO

Share code on the AIM: KIBO

ISIN: IE00B97C0C31

('Kibo' or 'the Company')

 

Dated: 21 May 2024

 

Kibo Energy PLC ('Kibo' or the 'Company')

 

Kibo Subsidiary Announces Business Update

 

Kibo Energy PLC (AIM: KIBO; AltX: KBO), the renewable energy-focused development company, announces a business update by its subsidiary Mast Energy Developments PLC ('MED'), a UK-based multi-asset owner, developer and operator in the rapidly growing flexible power market.

 

Further details can be found in the full MED RNS Announcement, which is available below and at med.energy.

 

-------------------------

Dated: 21 May 2024

 

Mast Energy Developments PLC ('MED' or 'the Company')

 

Business Update

 

Mast Energy Developments PLC, the UK-based multi-asset owner, developer and operator in the rapidly growing flexible power market, is pleased to announce an update regarding business operational and corporate matters.

 

Pyebridge

 

Further to the Company's previous announcements dated 11 April 2024, 26 April 2024 and most recently 7 May 2024 respectively, Pyebridge has received the 2nd Advance from RiverFort under the Funding Agreement, and it has made the associated payments to the site's O&M contractor, Cooper Östlund in terms of the Engineering Works contract regarding the full long-block overhaul of the first genset. The replacement genset has been shipped from the supplier, PowerUp in Austria, and is expected to arrive on site shortly. The necessary preparatory works on site to replace the existing genset with the refurbished unit are well advanced and on track. The expected timeline to completion of the work and commercial operations date of the refurbished genset as previously announced remains on schedule. The 2nd Advance also enables the acceleration of the overhaul of the first genset, and once the work is completed will result in a significant increase in additional revenue from the Pyebridge site and more importantly sooner than expected.

 

In the meantime, the site's other two gensets remain operational and will continue to generate revenue via its PPA with Statkraft. Additionally, Pyebridge will also keep receiving its current Capacity Market contract income from the government.

 

 

Project Capex Funding

 

Further to the Company's previous announcement dated 11 April 2024, most of MED's sites under development are either ready for construction, or already in early-stage construction. The progression of construction and commercial operations are subject to securing project capex funding. In order to address this key next step in respect of these projects' development lifecycle i.e. to get each project into production and generating revenue, MED is actively progressing discussions with various potential debt and equity funders. These discussions include banking institutions that have shown interest in providing funding.

 

JVA with Proventure Termination Update

 

Further to the Company's previous announcement dated 28 February 2024, stating Proventure's failure to remedy its material breach of the JVA, together with the exhaustive correspondence and actions on MED's part to accommodate and resolve the persistent delays by Proventure to fulfil its obligations under the JVA, the MED Board has decided to terminate the JVA with Proventure as previously announced. Under the provisions of the JVA and subsequent JVA Deed of Termination, MED is entitled to receive, and Proventure has an obligation to pay default penalties, in the sum of c. £435,000 (the "Default Penalties"). The Default Penalties have formally been accepted by Proventure, but regrettably none of the required Default Penalties, nor any part thereof have been paid to date. The Company subsequently reviewed the matter with its legal advisers, and is currently considering various options that will allow the Company to pursue the matter by taking appropriate further action against Proventure, its CEO, Mr. Srinivas Kona and other directors aimed at but not limited to recovering the Default Penalties.

 

In conjunction with the above, MED is also considering pursuing its available options for legal recourse against the initial JVA lead-investor, Seira Capital and its CEO, Mr. Srinivas Tangirala and other directors.

 

Pieter Krügel, MED CEO, commented"We are pleased that the overhaul of the first genset at Pyebridge is progressing well and on schedule. We are looking forward to completing the overhaul work within the expected timeline, and to move forward with the overhaul of the remaining two gensets. In the meantime, Pyebridge is operational and generating income.

 

"Concurrently we are actively progressing discussions with various interested funders regarding the capex funding of MED's construction-ready sites, in order to get each project into production and revenue generation as quickly as possible.

 

"We are looking forward to updating the market with further progress across the board in due course."

 

ENDS

 

This announcement contains inside information for the purposes of the UK version of the Market Abuse Regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ('UK MAR'). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

For further information please visit www.med.energy or contact:

Pieter Krügel

info@med.energy

Mast Energy Developments PLC

CEO

Jon Belliss

+44 (0)20 7399 9425

Novum Securities

Corporate Broker

 

_________________________

**ENDS**

 

For further information please visit www.kibo.energy or contact:

 

Louis Coetzee

info@kibo.energy

Kibo Energy PLC

Chief Executive Officer

James Biddle Roland Cornish

+44 207 628 3396

Beaumont Cornish Limited

Nominated Adviser

Claire Noyce

+44 20 3764 2341

Hybridan LLP

Joint Broker

Damon Heath

+44 207 186 9952

Shard Capital Partners LLP

Joint Broker

 

Beaumont Cornish Limited ('Beaumont Cornish') is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

 

Johannesburg

21 May 2024

Corporate and Designated Adviser

River Group

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBRGDUDBDDGSG
Date   Source Headline
13th Jun 20247:00 amRNSKibo Subsidiary Announces Business Update
12th Jun 20243:30 pmRNSUpdate to Corporate Restructuring
7th Jun 20242:07 pmRNSBroker Update
7th Jun 20247:00 amRNSCorporate Restructuring and Repositioning
30th May 20242:00 pmRNSKibo Subsidiary Announces AGM Results
23rd May 20243:55 pmRNSKibo Subsidiary Announces Business Update
21st May 20247:00 amRNSKibo Subsidiary Announces Business Update
9th May 202410:45 amRNSKibo Subsidiary MAST Major Shareholdings
8th May 20247:00 amRNSKibo Subsidiary Notice of Annual General Meeting
7th May 20247:00 amRNSKibo Subsidiary Business Update & Financing
30th Apr 20247:00 amRNSKibo Subsidiary MED Accounts’ Publication
26th Apr 20247:00 amRNSKibo Subsidiary Announces Business Update
23rd Apr 20242:30 pmRNSKibo Subsidiary Announces Major Shareholdings
11th Apr 20247:00 amRNSKibo Subsidiary MAST Announces Business Update
5th Mar 20247:00 amRNSIssue of Shares to Service Provider
4th Mar 202410:45 amRNSKibo Subsidiary Announces TR-1 Notification
28th Feb 20247:00 amRNSMAST New Funding Partner & Proventure Cancellation
21st Feb 20242:46 pmRNSHolding(s) in Company
20th Feb 20241:00 pmRNSKibo Subsidiary Announces TR-1 Notification
9th Feb 202412:45 pmRNSResults of Extraordinary General Meeting
5th Feb 20241:55 pmRNSKibo Subsidiary MAST Announces TR-1 Notification
31st Jan 202410:48 amRNSDirector/PDMR Shareholding
24th Jan 20243:45 pmRNSKibo Subsidiary MAST Announces TR-1 Notification
19th Jan 20241:52 pmRNSPDMR Share Sale
18th Jan 20247:00 amRNSNotice of Extraordinary General Meeting (“EGM”)
16th Jan 202410:50 amRNSCorrection on MED Shareholding
16th Jan 20247:00 amRNSKibo Strategy Update
11th Jan 20247:00 amRNSConversion, Equity Issue, TVR & Board Changes
8th Jan 20247:00 amRNSKibo Subsidiary Announces an Update on JVA
2nd Jan 20247:00 amRNSKibo Subsidiary - Further Update of Payment to JVA
22nd Dec 20237:00 amRNSKibo Subsidiary Announces JVA Completion Update
19th Dec 20232:00 pmRNSPDMR Share Sale
15th Dec 20237:00 amRNSSubsidiary Director Loan & PMDR Share Sale
11th Dec 20238:21 amRNSKibo Subsidiary Update JVA Completion Announcement
11th Dec 20237:00 amRNSMAST: Further Update to the Completion of JVA
7th Dec 20232:15 pmRNSResult of AGM
1st Dec 20237:00 amRNSKibo Subsidiary Announces Update of JVA
15th Nov 20237:00 amRNSNotice of AGM
13th Nov 20237:00 amRNSKibo UK Subsidiary JVA Interim Payment Update
26th Oct 20237:00 amRNSChange of Holding in Mast Energy Developments PLC
23rd Oct 20237:00 amRNSKibo Subsidiary - Update on the Completion of JVA
5th Oct 20237:00 amRNSPartial Settlement of Outstanding Shareholder Loan
4th Oct 20237:00 amRNSSale of Coal Interest in Botswana Power Project
29th Sep 20237:00 amRNSUnaudited Interim Results
22nd Sep 20237:00 amRNSKibo Subsidiary Announces Update on JVA Completion
1st Sep 20237:00 amRNSKibo Subsidiary Announces Further Update on JVA
25th Aug 20237:00 amRNSKibo Subsidiary MED Unaudited Interim Results
16th Aug 202310:10 amRNSClarification on Inaccurate Moneyweb Article
7th Aug 202310:25 amRNSDirector/PDMR Shareholding
4th Aug 20237:00 amRNSKibo Subsidiary Announces Update on JV Completion

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.